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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a major challenge for healthcare. Heterogeneities
in clinical manifestations and in disease progression are relevant traits in COPD with impact on patient
management and prognosis. It is hypothesized that COPD heterogeneity results from the interplay of mechanisms
governing three conceptually different phenomena: 1) pulmonary disease, 2) systemic effects of COPD and 3) co-
morbidity clustering.
Objectives: To assess the potential of systems medicine to better understand non-pulmonary determinants of
COPD heterogeneity. To transfer acquired knowledge to healthcare enhancing subject-specific health risk
assessment and stratification to improve management of chronic patients.
Method: Underlying mechanisms of skeletal muscle dysfunction and of co-morbidity clustering in COPD patients
were explored with strategies combining deterministic modelling and network medicine analyses using the
Biobridge dataset. An independent data driven analysis of co-morbidity clustering examining associated genes and
pathways was done (ICD9-CM data from Medicare, 13 million people). A targeted network analysis using the two
studies: skeletal muscle dysfunction and co-morbidity clustering explored shared pathways between them.
Results: (1) Evidence of abnormal regulation of pivotal skeletal muscle biological pathways and increased risk for
co-morbidity clustering was observed in COPD; (2) shared abnormal pathway regulation between skeletal muscle
dysfunction and co-morbidity clustering; and, (3) technological achievements of the projects were: (i) COPD
Knowledge Base; (ii) novel modelling approaches; (iii) Simulation Environment; and, (iv) three layers of Clinical
Decision Support Systems.
Conclusions: The project demonstrated the high potential of a systems medicine approach to address COPD
heterogeneity. Limiting factors for the project development were identified. They were relevant to shape strategies
fostering 4P Medicine for chronic patients. The concept of Digital Health Framework and the proposed roadmap
for its deployment constituted relevant project outcomes.
Introduction
Synergy-COPD (2011-14) [1] was an European Union pro-
ject, within a call dedicated to the Virtual Physiological
Human 7th Framework Program, conceived to explore the
potential of systems medicine to generate knowledge on
underlying mechanisms of chronic obstructive pulmonary
disease (COPD) heterogeneities observed in the patients
both in terms of clinical manifestations and disease pro-
gression [2,3]. A core component of the project was to
transfer of the acquired knowledge into the clinical arena
with a twofold purpose. Firstly, analysis of the role of a
systems approach to COPD heterogeneity to enhance
individual health risk assessment and stratification leading
to innovative patient management strategies. The second
purpose was to identify novel modalities for the interplay
between healthcare and biomedical research aiming at
fostering deployment of 4P Medicine for patients with
chronic disorders [4-6]. Ultimately, Synergy-COPD was
designed to generate outcomes in three different dimen-
sions: (i) biomedical area; (ii) information and communica-
tion technologies (ICT); and, (iii) transfer into healthcare.
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Biomedical area - The central biomedical hypothesis
in Synergy-COPD was that the classical “spill over” theory
[7,8] supporting that COPD heterogeneity is driven by the
pulmonary events of the disease is not valid. Alternatively,
we proposed that COPD heterogeneities result from the
interplay of mechanisms governing three conceptually dif-
ferent phenomena: 1) pulmonary disease, 2) systemic
effects of COPD and 3) co-morbidity clustering, each of
them with their own dynamics. To this end, a network
medicine approach [9-11] was used to investigate the
underlying mechanisms of two different actionable phe-
nomena showing negative impact on prognosis of COPD
patients: (i) skeletal muscle dysfunction/wasting, as a hall-
mark of systemic manifestations of the disease [12]; and,
(ii) co-morbidity clustering in these patients [13-15]. Two
subsidiary biomedical aims were: (i) to explore shared
abnormalities between the two phenomena, skeletal mus-
cle dysfunction and risk of co-morbidity clustering; and,
(ii) to investigate the relationships between skeletal muscle
dysfunction and nitroso-redox disequilibrium [12] with
focus on assessing the potential of a quantitative analysis
of the relationships between cellular hypoxia and abnor-
mal reactive oxygen species (ROS) generation.
Targeted ICT developments - Three well differen-
tiated ICT developments were carried out during the pro-
ject lifetime. Firstly, the COPD Knowledge-Base (COPDkb)
from clinical and experimental data, text-mining results
and public databases [16]. The COPDkb combines genetic
information with molecular, physiological and clinical data.
It provides data integration and semantic mapping con-
nected with mathematical modelling and the Simulation
Environment [17]. The second group of ICT developments
was associated with different types of mathematical model-
ling [18] aiming at addressing the biomedical questions
alluded to above. They encompassed different types of: (i)
qualitative and semi-quantitative network analyses; (ii) clas-
sical mechanistic modelling based on ordinary differential
equations (ODE), as well as (iii) research on the interplay
between network analysis and mechanistic modelling. The
third ICT product was the Simulation Environment (SE)
[17] aiming at supporting biomedical researchers to con-
currently run heterogeneous modelling approaches that
may have complementary roles in exploring a given biome-
dical phenomenon.
Transfer to healthcare - A last and most important
aspect of the project was the transfer of the acquired
knowledge, as novel rules for patient management, into
the clinical practice through the generation of clinical
decision support systems (CDSS) embedded into the
clinical processes defined within different integrated
care services (ICS) for chronic patient management
[19,20]. The project also assessed two different deploy-
ment strategies for these CDSS, in Barcelona and in the
United Kingdom.
The ambition of Synergy-COPD, and the complexities
faced during the project lifetime, generated deviations
from the initial working plans and forced subsequent
adaptations that often resulted in an added value for the
entire operation. It is of note that the triggering factors
generating project deviations covered a wide spectrum
of characteristics that are systematically addressed
below. The current manuscript: (i) summarizes the main
outcomes of Synergy-COPD; (ii) analyses the lessons
learnt during the project lifetime; (iii) identifies some of
the key challenges to be faced for a successful imple-
mentation of 4P medicine for chronic patients; and,
(iv) characterizes opportunities for further developments
in systems medicine.
Biomedical outcomes
The central biomedical hypothesis has been described
above and it was extensively presented in [19,21]
wherein COPD heterogeneity is analysed in detail. The
biomedical rationale of the entire project was based on
the results of an unbiased clustering analysis of approxi-
mately 342 clinically stable COPD patients characterized
after their first hospitalization and followed-up during a
5-year period [22]. The PAC_COPD study [22] identi-
fied and prospectively validated three COPD subtypes:
(i) Group I, severe respiratory COPD; (ii) Group II,
moderate respiratory COPD patients in whom the most
distinctive trait was a dissociation between severe
emphysema score together with mild to moderate air-
way remodelling leading and moderate airflow limita-
tion, as expressed by forced expiratory volume during
the first second (FEV1); and, (iii) Group III, including
COPD patients in whom the most characteristic trait
was co-morbidity clustering, mainly cardiovascular dis-
orders (CVD), type II diabetes mellitus (T2DM) often
accompanied by metabolic syndrome (MS). It is of note
that skeletal muscle dysfunction was a transversal char-
acteristic with patients distributed in all three PAC_
COPD groups [22]. The main biomedical findings of the
studies carried out in Synergy-COPD were:
Abnormal regulation of relevant skeletal muscle
biological pathways - Integrative multilevel analyses of
skeletal muscle of healthy subjects and COPD patients
[23-26] including different “omics” layers (transcriptomics,
epigenetics, proteomics and metabolomics), physiological
characteristics and clinical information generated strong
evidence of abnormal regulation of muscle bioenergetics
both at baseline and, in particular, after the perturbation
of the biological system by a standard endurance training
protocol. Abnormal training-induced adaptations were
observed at several different levels of the mitochondrial
respiratory chain, but also in the interplay between oxida-
tive and glycolytic pathways, as well in fatty acids metabo-
lism. The network analysis indicated abnormalities in key
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metabolic pathways governing skeletal muscle bioener-
getics [24] and ribosome biogenesis [27] such as mTOR
[12,28-30] and its interplay with insulin signalling pathway
[31]. Interestingly, the different analyses carried out in
COPD patients consistently showed abnormal relation-
ships between cytokines and tissue remodelling at baseline
and after training [24,32].
Increased risk of co-morbid conditions in COPD
patients - Using 13 million health records from U.S.
Medicare [33,34], the project identified 27 disease groups
(DG) with significantly elevated risks to co-occur with
COPD that increased with ageing. These groups included
both well-established associations like CVD or lung can-
cer, but also unexpected ones, like digestive track disor-
ders, that could be interesting candidates for more
focused follow-up investigations. For each DG, we con-
structed a comprehensive list of known associated genes
from the literature and by performing a pathway enrich-
ment analysis a number of pathways that are shared
between different disease groups were identified, suggest-
ing that the observed co-morbidities are indeed rooted in
shared molecular mechanisms. By further inspecting the
genes within prevalent pathways, the project was able to
identify a number of genes with the potential to charac-
terize COPD co-morbidities. On-going analyses on
potential biomarkers predicting the level of co-morbidity
remain to be validated in further studies.
Overall, the biomedical results seem to support the
central hypothesis of the project indicating that abnor-
mal regulation of pivotal pathways at systemic level can
contribute to both co-morbidity clustering and skeletal
muscle dysfunction in these patients. Moreover, the ana-
lyses support a potential causal role for nitroso-redox
disequilibrium contributing [35] to the abnormal path-
way regulation as observed in COPD. Accordingly, indi-
vidual susceptibility to deregulation of metabolic
pathways, together with potential epigenetic mechanisms
likely associated with aerobic capacity, may play a role
modulating both systemic effects and co-morbidity clus-
tering in these patients, beyond well known risk factors
such as tobacco smoking. Despite that the results from
different animal experiments carried out during the pro-
ject lifetime support the above interpretations of the
current results, we fully acknowledge that further valida-
tion of the current speculations is required before we
move to transfer of knowledge into the clinical scenario,
as discussed in the following sections of the current
manuscript.
An ancillary aim of the project was the analysis of
group II of the PAC_COPD study [22] using the
mechanistic model of pulmonary spatial heterogeneities
as described in [19] and in [36] in order to generate
rules for identification of this subset of COPD patients
in primary care. The rationale behind this approach is
that this subset of COPD patients could be a candidate
for screening programs for early diagnosis of lung can-
cer which is one of the priorities in respiratory medi-
cine. The literature appears to indicate that dissociation
between high emphysema score and mild airway remo-
delling is associated with a higher probability of devel-
oping lung cancer [37,38]. Unfortunately, the maturity
of the modelling development did not allow completion
of the analyses as initially planned.
Targeted ICT developments
COPD knowledge base (COPDkb) - During the project
lifetime, the COPDkb [16,39] has been extended to inte-
grate over 40 public data sources on functional interac-
tion (e.g. signal transduction, transcriptional regulation,
protein-protein interaction, gene-disease association).
Also, integration of COPD-specific expression and co-
morbidity networks connecting over 6.000 genes/proteins
with physiological parameters and disease states has been
accomplished. Three mathematical models describing
different aspects of systemic effects of COPD were con-
nected to clinical and experimental data. The technical
architecture of the user interface was enhanced in order
to provide browser-based access and form-based
searches, as described in detail in [39]. A network search
enables the use of interconnecting information and the
generation of disease-specific sub-networks from general
knowledge. Integration with the Synergy-COPD Simula-
tion Environment [17] enables multi-scale integrated
simulation of individual computational models. The cur-
rent COPDkb [39] is the only publicly available knowl-
edge resource dedicated to COPD which combines
genetic information with molecular, physiological and
clinical data, as well as mathematical modelling. Its inte-
grated analysis functions provide overviews about clinical
trends and connections while its semantically mapped
content enables complex analysis approaches. The
COPDkb has been planned to be offered as a repository
to publish and semantically integrate data from relevant
clinical trials. It is currently freely available after registra-
tion at www.copdknowledgebase.eu.
Modelling achievements - The project combined sev-
eral modelling approaches, probabilistic [40] and mechan-
istic [41-43], to address the three biomedical analyses
alluded to above, namely: (i) skeletal muscle dysfunction;
(ii) co-morbidity clustering, as well as (iii) group II from
the PAC_COPD study [22], as indicated in [19]. Moreover,
novel modelling techniques, Bayesian analyses [44] and
Thomas network formalism [45,46], addressing the inter-
play between probabilistic and mechanistic modelling
were explored aiming at expanding the potential of future
systems-oriented analyses of biological phenomena. A
detailed description of the project’s achievements in this
area can be found in [18].
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All in all, both the modelling developments and the
strategies adopted showed to be useful to explore the bio-
medical challenges of the project and to identify potential
biomarkers. Moreover, the interplay between the two
main modelling strategies indicate the potential of prob-
abilistic modelling, Thomas formalism [45,46], to contri-
bute to parameter refinement in mechanistic modelling
(e.g. enhanced parameter estimation for mitochondrial
function in the integrated model, [18]. Also, predictive
modelling showed potential to assess the multi-scale
impact of the outcomes generated by mechanistic model-
ling (e.g. consequences of abnormally high mitochondrial
ROS generation on inflammatory responses or tissue
remodelling). However, some limitations in modelling
developments and in their clinical impact due to different
reasons shall be acknowledged. Main lessons learnt in
this area, as well as the associated challenges identified
during the project lifetime are described in the following
section of the current manuscript.
Simulation environment - It was developed as a sup-
porting tool for bio-researchers aiming at studying
COPD by running concurrent computational models.
The Simulation Environment is composed of two main
modules to control and coordinate information-related
processes. One of these modules is the graphical visuali-
zation environment, the interface through which the
user interacts with the models. The other module is the
simulation workflow management system. Detailed func-
tionalities and interoperability with the COPDkb are
described in detail in [39]. Lessons learnt through the
assessment of the Simulation Environment are also dis-
cussed in the following section.
Transfer to healthcare
As indicated above and described in detail in [18], the
modelling achievements of the project were far from
being mature for clinical application, such that subject-
specific predictive modelling generating rules to directly
feed clinical decision support systems (CDSS) could not
be developed, as initially planned. However, the research
team agreed that the main objectives of the transfer to
healthcare could be achievable by combined consoli-
dated knowledge on COPD with emerging knowledge
from the project. The latter, despite the lack of proper
validation, could be useful to generate CDSS aiming at
filling well identified clinical gaps. It is fully acknowl-
edged that those CDSS should be further evaluated for
clinical use beyond the project lifetime. As discussed in
the following section, the strategy finally adopted
allowed to overcome some of the limitations of the
modelling and facilitated the identification of key bottle
necks for future implementation of 4P medicine.
The research team identified two main areas to be
considered under the current subheading analysing the
transfer to healthcare: (i) steps associated to CDSS genera-
tion and deployment; and, (ii) factors modulating the
interplay between healthcare and systems-oriented biome-
dical research.
Generation of CDSS in Synergy-COPD - The follow-
ing three main steps should be considered for the devel-
opment of CDSS: (i) generation of the rules feeding each
CDSS either automatically from computer modelling
and/or through the rationale provided by existing knowl-
edge; (ii) clinical validation and acceptability of the rules
by the clinical users; and (iii) interoperability with the
ICT platform supporting integrated care services (ICS)
implying that the CDSS are embedded into the clinical
process and show both usability and applicability. In the
project, three different families of CDSS, encompassing:
(i) diagnosis; (ii) stratification; and (iii) management of
COPD with a patient-oriented approach, were conceived
with different degrees of development and validation.
Firstly, the suite of CDSS included under the umbrella of
the COPD case finding program covers four well defined
aims: (i) articulates informal care (pharmacy offices) and
formal care (primary care) for early diagnosis of COPD,
(ii) ensures remote, web-supported, quality control of
testing and assistance to non-specialized professionals;
(iii) provides accessibility and interoperability of the testing
across healthcare tiers; and, (iv) explores the potential for
both regional deployment of the forced spirometry testing
program, as well as generalization of the approach to
other testing procedures to enforce the transfer of com-
plexity to primary care and to the community. To this
end, developments done within Synergy-COPD were
articulated with achievements from previous deployment
projects [47,48] which demonstrated to be highly produc-
tive. Briefly, all key aspects of the COPD case finding
program had both qualitative and robust quantitative eva-
luations, as reported in [20]. The regional deployment of
the program in Catalonia was initiated by November 2013
and its complete clinical validation through a large cluster
RCT is expected to be completed by the end of 2015.
A second block corresponds to the suite of CDSS
enhancing applicability of the 2011 GOLD update [19,20],
as well as proposals for stratification of COPD patients.
These CDSS are addressing three main goals: (1) applic-
ability of GOLD within an integrated electronic health
record; (ii) facilitate future comparative analyses among
different approaches for assessing health risk in COPD
and deciding on subject-specific stratification; and, (iii)
address early disease interventions with emphasis on life-
style being physical activity, nutrition and enhanced adher-
ence through self-management the target ones. In sum-
mary, this suite of CDSS should support the design of
early cost-effective interventions with preventive purposes,
facilitate the interplay between community (informal care),
primary care and with specialized professionals. This
Miralles et al. Journal of Translational Medicine 2014, 12(Suppl 2):S12
http://www.translational-medicine.com/content/12/S2/S12
Page 4 of 8
family of CDSS was conceptually developed and qualita-
tively assessed, but it is not technological in place mainly
because deployment is modulated by two main on-going
processes: (i) build-up consensus among primary care
teams; and, (ii) achievement of interoperability at health
system levels. Finally, the third block of CDSS corresponds
to community-based management of patients with
advanced disease stages currently in the pipeline for regio-
nal deployment. The three layers of CDDS provide a
coherent spectrum of actions enhancing management of
chronic patients.
Interplay between healthcare and systems-oriented
biomedical research - The project identified that
deployment of 4P medicine involving implementation of
sound strategies for patient health risk assessment and
stratification generating two key requirements. Firstly,
articulation between informal care and healthcare allow-
ing incorporation of non-clinical information into
patient management; that is, data on patient adherence
profile, lifestyle (physical activity, nutritional habits,
addictions), social support needs, environmental and
societal factors that have a well accepted impact on
health status and survival. The use of the personal
health folder (PHF) enriched with accredited, custo-
mized apps that are properly interoperable with the
electronic health record (EHR) may cover a twofold aim:
(i) articulation of non-clinical and clinical information;
and, (ii) empower patients for self-management.
A second major requirement is the articulation of the
scenario described above (PHF + EHR) with a novel
type of systems-oriented biomedical research platform
ensuring continuous cross-fertilization between research
and patient care. This ideal setting would cover both
incorporation of non-biomedical data into predictive
modelling and provide dynamic modelling approaches
that should facilitate the way toward truly personalized
medicine. Such a proposal has been described in more
detail in [6], under the concept of Digital Health Frame-
work (DHF), wherein the roadmap for its stepwise
deployment is analysed.
Main challenges beyond Synergy-COPD
Major lessons learnt from the analysis of the limitations
faced during the development of the project can be
grouped in three major clusters: (i) available datasets;
(ii) maturity of the field; and, (iii) need for societal
changes. The assessment of these three areas helped to
identify major challenges to be faced beyond Synergy-
COPD:
Available datasets - Despite the current exponential
generation of large amounts of biomedical data of different
nature, several factors associated to availability of appro-
priate datasets have limited the transfer of the project
outcomes on mechanisms of skeletal muscle dysfunction
and co-morbidity clustering closer to clinical application.
The following limiting aspects were identified: (i) the frag-
mented nature of the available datasets; (ii) insufficient
context-specific information; and, (iii) the lack of large
datasets with proper experimental designs including multi-
level “omics” information and clinically-driven hypotheses.
Additional problems encountered throughout the pro-
ject lifetime have been: (i) insufficient harmonization of
medical coding across countries and within large longitu-
dinal datasets [49-51]; (ii) gaps in semantic interoperability
with large variations in disease definitions and coding;
(iii) publicly available information biased toward well
established and expected diseases and their underlying
mechanisms [52-54]; (iv) lack of multilevel “omics” infor-
mation bridging between GWAS information and pheno-
typic characterization [55]; and, (v) lack of accompanying
non-clinical information (environmental, lifestyle, socioe-
conomic factors) in bio-banking data. In summary, the
characteristics of the available datasets had a negative
impact on the project precluding the generation of sub-
ject-specific predictive modelling. But, they also consti-
tuted a limitation to validate the explored novel modelling
approaches (e.g. Bayesian analysis and Thomas formalism)
that should facilitate the interplay between probabilistic
and mechanistic modelling for further characterization of
complex biological processes. In this regard, policies
promoting data-sharing are highly recommended.
Maturity of the field - Mechanistic modelling techni-
ques have shown usefulness to characterize biological
mechanisms and to provide quantitative assessment of the
phenomena analysed [18], but they have serious limita-
tions to address complex biological phenomena. In con-
trast, network medicine approaches [34,40] based on
statistical predictive models [56,57] seem suitable to
address complex biomedical phenomena when large
amount of data are available. Moreover, high-throughput
analysis [58,59] have shown that canonical analysis of bio-
logical pathways is too simplistic not reflecting the real
complexity of interconnectedness of biological networks
[60]. It is of note, however, that the high expectations gen-
erated by emerging high-throughput methods are not
balanced by a sufficient degree of maturity yet [61,62].
Societal changes - The project clearly identified that
major organizational and technological changes are
required to pave the way for a credible transition toward
4P medicine. Some of the key requirements for such a
transition are described in [6] within the concept of Digi-
tal Health Framework. But, cultural factors such as: (i)
workforce preparation, (ii) evolving concepts in terms of
ethical factors relative to privacy of information transfer
and information sharing; and, (iii) development of novel
business environments fulfilling the requirements of the
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novel scenario are relevant elements to be taken into
account in the definition of strategies leading to a suc-
cessful implementation of the change.
It must be emphasized that the identification of the
limiting elements alluded to above does not define at all
a negative landscape for systems-oriented research in
the biomedical area. On the contrary, one of the most
important outcomes of Synergy-COPD has been the
identification of the challenges to be faced and the defi-
nition of innovative strategies to adequately overcome
the limiting factors alluded to above that should lead to
unprecedented developments in the medical practice.
Opportunities identified during the project
lifetime
A profound change in the health paradigm is being fos-
tered by the convergence of three major driving forces ori-
ginated by the needs for: (i) coping with the epidemics of
chronic conditions through implementation of the
Chronic Care model; (ii) achieving cost-containment of
healthcare through generation of health efficiencies; and,
(iii) transferring to clinical practice a mechanisms-based
approach to disease based on systems medicine [9,63]. All
in all, the emerging scenario is exceedingly favourable for
the convergence between integrated care and systems
medicine as an efficient way to accelerate a mature deploy-
ment of 4P medicine for chronic patients. The outcomes
of the Synergy-COPD project clearly reinforce such an
orientation for future developments in the field.
The acknowledgment of the complexities faced during
the project lifespan delineates the need for planning a
building-blocks strategy in future endeavours designed to
achieve further progress in the area. Moreover, the con-
cept of Digital Health Framework provides the rationale
for prioritization of the ICT developments, as identified in
the proposed roadmap for the deployment.
It is currently well accepted that the Chronic Care
model through deployment of integrated care services sup-
ported by information and communication technologies
(ICS_ICT) can contribute to enhance health outcomes
without increasing overall costs of the health system. Such
a generation of healthcare efficiencies is partly achieved by
the transfer of complexities from specialized to primary
care and to the community. It is reasonable to hypothesize
that the generation of health efficiencies can be markedly
boosted by: (i) promoting a more active role of citizens,
patients and carers in self-management and co-design of
the services; and, (ii) fostering cost-effective preventive
strategies aiming at modulating disease progress. These
two strategic proposals require adoption of the novel
health paradigm that involves bridging traditional health-
care delivery (i.e. formal care) and informal care (e.g.
patient self-management, wellness programs, social care,
etc.) through adoption of citizen’s (patient’s) personal
health records as management tools. In this new scenario,
the correct articulation of patient gateways and mobile
devices (mHealth) [64] is promising to empower, for the
first time, an efficient channel enhancing accessibility to
the health system, facilitating monitoring and including
patient’s behavioural and environmental factors into health
management. The ultimate goal of patient gateways is to
support cost-effective preventive interventions to modu-
late the evolution of the disease which might represent tre-
mendous sources of efficiencies if in-place.
Moreover, the analysis of the lessons learnt during the
Synergy-COPD project facilitates the identification of
specific challenge-driven opportunities in all the areas
described above. A proper prioritization of future actions
following the general recommendations generated by the
project should contribute to make 4P medicine for
chronic patients a successful reality.
Conclusions
The Synergy-COPD project has demonstrated that a sys-
tems-oriented research on COPD heterogeneity gener-
ated novel knowledge, not achievable through classical
methods. In the project, COPD was targeted as a use
case because of the high prevalence and impact of the
disease, as well as the relevance of COPD heterogeneity
for subject-based health risk assessment and stratification
in the clinical arena. Moreover, COPD showed an ele-
vated potential for generalization of the research findings
to other prevalent chronic disorders.
The concept of Digital Health Framework developed in
the project and the roadmap for its implementation
involves an overall strategy for the transition from current
healthcare practice to a novel scenario fostering cross-talk
between informal care, healthcare system and systems-
oriented biomedical research that shall facilitate implemen-
tation of 4P medicine for chronic patients.
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